Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 673-681

  Leahy, Jennifer T ^a   Chu Shore, Catherine J ^a,b   Fisher, Janet L ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Benzodiazepine; Epilepsy; Gamma aminobutyric acid; Pediatric; Pharmacoresistance

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; FELBAMATE; LAMOTRIGINE; MYSTAN; NORCLOBAZAM; ONFI; PLACEBO; RUFINAMIDE; STIRIPENTOL; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADD ON THERAPY; ADJUVANT THERAPY; ANTICONVULSANT ACTIVITY; APLASTIC ANEMIA; ARTICLE; ATAXIA; BEHAVIOR DISORDER; BRAIN SURGERY; COMBINATION CHEMOTHERAPY; CONSTIPATION; CORPUS CALLOSOTOMY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; EPILEPSY; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSALIVATION; IRRITABILITY; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NONHUMAN; PANCREATITIS; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TRANQUILIZING ACTIVITY; TREATMENT FAILURE; TREATMENT RESPONSE; VAGUS NERVE STIMULATION; VOMITING;

EID: 80955132677     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Markand O. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol. 2003;20(6):426-441.
2. Ng YT, Collins SD. Clobazam. Neurotherapeutics. 2007;4(1): 138-144.
3. van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008;4(6): 1001-1019.
4. Michoulas A, Farrell K. Medical management of Lennox-Gastaut syndrome. CNS Drugs. 2010;24(5):363-374.
5. Camfield P. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011;52 Suppl 5:3-9.
6. Arzimanoglou A, French J, Blume W, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82-93.
7. Hancock EC, Cross HH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2009;8(3):CD003277.
8. Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009;50(5):1158-1166.
9. Shields WD. Catastrophic epilepsy in childhood. Epilepsia. 2000;41 Suppl 2:S2-S6.
10. E. Infantile spasms and Lennox-Gastaut syndrome. J Child Neurol. 2002;17 Suppl 2:2S9-2S22.
11. Camfield P, Camfield C. Epileptic syndromes in childhood: clinical features, outcomes, and treatment. Epilepsia. 2002;43 Suppl 3: 27-32.
12. Montouris G. Rational approach to treatment options for Lennox- Gastaut syndrome. Epilepsia. 2011;52 Suppl 5:10-20.
13. Wheless JW, Clark DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol. 2005;20 Suppl 1:S1-S56.
14. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Discord. 2007;9(4):353-412.
15. Schmidt D, Bourgeois B. A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf. 2000;22(6):467-477.
16. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities. III. US experience since 1986. Neurology. 1996;46(2):465-469.
17. O'Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S. Felbamate- associated fatal acute hepatic necrosis. Neurology. 1996; 46(5):1457-1459.
18. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia. 1997;38(12):1265-1269.
19. Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML. Felbamate: consensus of current clinical experience. Epilepsy Res. 2006;71(2-3):89-101.
20. Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut Syndrome). Epilepsia. 1997;38(1):68-73.
21. Farrell K, Connolly MB, Munn R, Peng S, MacWilliams LM. Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy. Pediatr Neurol. 1997;16(3):201-205.
22. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med. 1997;337(25):1807-1812.
23. Dooley J, Camfield P, Gordon K, Camfield C, Wirrell E, Smith E. Lamotrigine- induced rash in children. Neurology. 1996;46(1):240-242.
24. Schlumberger E, Chavez F, Placios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia. 1994;35(2):359-367.
25. Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology. 2000;55(4):588-591.
26. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology. 1996;46(6):1684-1690.
27. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999;52(2):321-327.
28. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;69(5):636-641.
29. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950-1958.
30. Chu-Shore CJ, Thiele EA. New drugs for pediatric epilepsy. Semin Pediatr Neurol. 2010;17(4):214-223.
31. Freeman JM, Vining EP, Pillas DJ, Pyzik PL, Casey JC, Kelly MT. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics. 1998;102(6):1358-1363.
32. Freeman JM, Vining EP, Kossoff EH, Pyzik PL, Ye X, Goodman SN. A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia. 2009;50(2):322-325.
33. Vining EP, Freeman JM, Ballaban-Gil K, et al. A multicenter study of the efficacy of the ketogenic diet. Arch Neurol. 1998;55(11):1433-1437.
34. Seo JH, Lee YM, Lee JS, Jang HC, Kim HD. Efficacy and tolerability of the ketogenic diet according to lipid:nonlipid ratios - comparison of 3:1 with 4:1 diet. Epilepsia. 2007;48(4):801-805.
35. Rychlicki F, Zamponi N, Trignani R, Ricciuti RA, Iacoangeli M, Scerrati M. Vagus nerve stimulation: clinical experience in drugresistant pediatric epileptic patients. Seizure. 2006;15(6):483-490.
36. Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia. 2001;42(9):1148-1152.
37. Rossignol E, Lortie A, Thomas T, et al. Vagus nerve stimulation in pediatric epileptic syndromes. Seizure. 2009;18(1):34-37.
38. Cukiert A, Burattini JA, Mariani PP, et al. Extended, one-stage callosal section for treatment of refractory secondarily generalized epilepsy in patients with Lennox-Gastaut and Lennox-like syndromes. Epilepsia. 2006;47(2):371-374.
39. You SJ, Lee JK, Ko TS. Epilepsy surgery in a patient with Lennox- Gastaut syndrome and cortical dysplasia. Brain Dev. 2007;29: 167-170.
40. Hanks GW. Clobazam: pharmacological and therapeutic profile. Br J Clin Pharmacol. 1979;7 Suppl 1:151S-155S.
41. Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118(2): 69-86.
42. Barzaghi F, Fournex R, Mantegazza P. Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodiazepine), a new psychotherapeutic agent. Arzneimittelforschung. 1973;23(5):683-686.
43. Gastaut H, Low MD. Antiepileptic properties of clobazam, a 1-5 benzodiazepine, in man. Epilepsia. 1979;20(4):437-446.
44. Giraud C, Tran A, Rey E, Vincent J, Tréluyer JM, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32(11):1279-1286.
45. Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34(4):608-611.
46. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995;29(3):192-209.
47. Contin M, Sangiorgi S, Riva R, Parmeggiani A, Abani F, Baruzzi A. Evidence of polymorphic CYP2C19 involvement in the human metabolism of n-desmethylclobazam. Ther Drug Monit. 2002;24(6): 737-741.
48. Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004;26(8):530-534.
49. Seo T, Nagata R, Ishitsu T, et al. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics. 2008;9(5):527-537.
50. Meldrum BS, Chapman AG, Horton RW. Clobazam: anticonvulsant action in animal models of epilepsy [proceedings]. Br J Clin Pharmacol. 1979;7 Suppl 1:59S-60S.
51. Löscher W, Rundfeldt C, Hönack D, Ebert U. Long-term studies on anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. I. Comparison of diazepam, clobazam and abercarnil. J Pharm Exp Ther. 1996;279(2):561-572.
52. Šlamberová R, Mareš P, Vorlícček J. Clobazam exerts an anticonvulsant action in immature rats. Physiol Res. 1998;47(4):301-305.
53. Miura Y, Amano S, Torii R, Ihara N. Clobazam shows a different antiepileptic action profile from clonazepam and zonisamide in Ihara epileptic rats. Epilepsy Res. 2002;49(3):189-202.
54. Luszczki JJ, Trojnar MK, Ratnaraj N, Patsalos PN, Czuczwar SJ. Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model. Epilepsy Res. 2010;90(3): 188-198.
55. Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M. Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia. 1996;37(8):728-735.
56. Gatta E, Cupello A, Di Braccio M, et al. New 1,5-benzodiazepine compounds: activity at native GABA(A) receptors. Neuroscience. 2010;166(3):917-923.
57. Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006;47(4):704-716.
58. Whiting PJ, Bonnert TP, McKernan RM, et al. Molecular and functional diversity of the expanding GABA-A receptor gene family. Ann NY Acad Sci. 1999;868:645-653.
59. Galanopoulou AS. GABA(A) receptors in normal development and seizures: friends or foes? Curr Neuropharmacol. 2008;6(1):1-20.
60. Korpi ER, Gründer G, Lüddens H. Drug interactions at GABA(A) receptors. Prog Neurobiol. 2002;67(2):113-159.
61. Ogris W, Pöltl A, Hauer B, et al. Affinity of various benzodiazepine site ligands in mice with a point mutation in the GABA receptor gamma2 subunit. Biochem Pharmacol. 2004;68(8):1621-1629.
62. Fisher JL. Interactions between modulators of the GABA(A) receptor: Stiripentol and benzodiazepines. Eur J Pharmacol. 2011;654(2): 160-165.
63. Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S. Pharmacological properties of GABAA receptors containing gamma1 subunits. Mol Pharmacol. 2006;69(2):640-649.
64. Li M, Szabo A, Rosenberg HC. Evaluation of native GABA(A) receptors containing an alpha 5 subunit. Eur J Pharmacol. 2001;413(1):63-72.
65. Rudolph U, Crestani F, Möhler H. GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci. 2001;22(4):188-194.
66. Rudolph U, Möhler H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol. 2006;6(1):18-23.
67. Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci U S A. 2005;102(3):915-920.
68. Doi T, Ueda Y, Tokumaru J, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. Brain Res Mol Brain Res. 2005;142(2):91-96.
69. Ueda Y, Doi T, Tokumaru J, et al. Collapse of extracellular glutamate regulation during epileptogenesis: down-regulation and functional failure of glutamate transporter function in rats with chronic seizures induced by kainic acid. J Neurochem. 2001;76(3):892-900.
70. Mehndiratta MM, Krishnamurthy M, Rajesh KN, Singh G. Clobazam monotherapy in drug naïve adult patients with epilepsy. Seizure. 2003;12(4):226-228.
71. Haigh JR, Pullar T, Gent JP, Dailley C, Feely M. N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy? Br J Clin Pharmacol. 1987;23(2):213-218.
72. Kinoshita M, Ikeda A, Begum T, Terada K, Shibasaki H. Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB. J Neurol Sci. 2007;263(1-2):44-48.
73. Whiting PJ. GABA-A receptors: a viable target for novel anxiolytics? Curr Opin Pharmacol. 2006;6(1):24-29.
74. Munn R, Farell K. Open study of clobazam in refractory epilepsy. Pediatr Neurol. 1993;9(6):465-469.
75. Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia. 1998;39(9):952-959.
76. Mills JK, Lewis TG, Mughal K, Ali I, Ugur A, Whitehouse WP. Retention rate of clobazam, topiramate, and lamotrigine in children with intractable epilepsy at 1 year. Seizure. 2011;20(5):402-405.
77. Montenegro MA, Arif H, Nahm EA, Resor SR Jr, Hirsch LJ. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center. Clin Neuropharmacol. 2008;31(6):333-338.
78. Farrell K. Benzodiazepines in the treatment of children with epilepsy. Epilepsia. 1986;27 Suppl 1:S45-S52.
79. Jan MM, Shaabat AO. Clobazam for the treatment of intractable childhood epilepsy. Saudi Med J. 2000;21(7):622-624.
80. Sugai K. Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan. Epilepsia. 2004;45 Suppl 8:S20-S25.
81. Kalra V, Seth R, Mishra D, Saha NC. Clobazam in refractory childhood epilepsy. Indian J Pediatr. 2010;77(3):263-266.
82. Sheth RD, Ronen GM, Goulden KJ, Penney S, Bodensteiner JB. Clobazam for intractable pediatric epilepsy. J Child Neurol. 1995;10(3): 205-208.
83. Vadja FJ, Bladin PF, Parsons BJ. Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy. Clin Exp Neurol. 1985;21:177-182.
84. da Silveira MR, Mentenegro MA, Franzon RC, Guerreiro CA, Geurreiro MM. Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy. Arq Neuropsiquiatr. 2006;64(3B):705-710.
85. Silva RC, Montenegro MA, Geurreiro CA, Geurreiro MM. Clobazam as add-on therapy in children with epileptic encephalopathy. Can J Neurol Sci. 2006;33(2):209-213.
86. Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci. 1990;17(3):317-319.
87. Conry JA, Ng Y, Drummond R, Stolle J, Sagar S. Efficacy and safety of clobazam in the treatment of seizures associated with Lennox-Gastaut syndrome: results of a phase III trial [abstract]. Proceedings of the 64th Annual Meeting of the American Epilepsy Society; December 3-7, 2010; San Antonio, Tx: 2010:1.283.
88. Trojnar MK, Wojtal K, Trojnar MP, Czuczwar SJ. Stiripentol. A novel antiepileptic drug. Pharmacol Rep. 2005;57(2):154-160.
89. Chiron C, Dulac O. The pharmacological treatment of Dravet syndrome. Epilepsia. 2011;52 Suppl 2:72-75.
90. Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia. 2011;52 Suppl 2:76-78.
91. Theis JG, Koren G, Daneman R, et al. Interactions of clobazam with conventional antiepileptics in children. J Child Neurol. 1997;12(3):208-213.